Bristol-Myers Squibb and ZymoGenetics reported that the administration of the investigational compound PEG-Interferon lambda in combination with ribavirin significantly reduced hepatitis C virus (HCV) RNA in 10 patients and was well-tolerated in patients with relapsed HCV in an ongoing Phase 1b clinical trial. This trial was designed to evaluate the safety and antiviral activity of PEG-Interferon lambda as monotherapy or in combination with ribavirin in genotype 1 HCV patients with relapsed disease. Antiviral activity was observed at all dose levels tested either as a single agent or in combination with ribavirin.
PEG-Interferon lambda (IL-29) is a novel type 3 interferon.
For more information call (800) 321-1335 or visit www.bms.com/research/pipeline.